{"id":"E10","lang":"en","question":"How are TaiMed, Theratechnologies, and Trogarzo connected?","answer":[{"text":"TaiMed identifies Theratechnologies as its exclusive U.S. commercialization partner for Trogarzo (ibalizumab-uiyk).","fact_ids":["f1"]},{"text":"TaiMed’s 2025 statement says their longstanding agreement for marketing and distributing Trogarzo in the United States and Canada remains in effect despite the announced Future Pak transaction.","fact_ids":["f2"]}],"facts":[{"id":"f1","claim":"Product and US partner","value":"Trogarzo (ibalizumab-uiyk); Theratechnologies is TaiMed’s exclusive U.S. commercialization partner","as_of":"2026-10-22","source":"https://www.taimedbiologics.com/article_d.php?id=2922&lang=en&tb=5","quote":"exclusive commercialization partner"},{"id":"f2","claim":"Distribution relationship","value":"TaiMed–Theratechnologies agreement covers marketing and distribution in the U.S. and Canada","as_of":"2026-10-22","source":"https://www.taimedbiologics.com/article_d.php?id=2922&lang=en&tb=5","quote":"in the U.S. and Canada remains in effect"}],"undisclosed":{"text":"The checked public partnership-continuity statement does not disclose the full contract, current transfer-price formula or product-level profit split.","source":"https://www.taimedbiologics.com/article_d.php?id=2922&lang=en&tb=5","as_of":"2026-10-22","quote":"TaiMed Biologics","scope":"Only the specific primary documents cited in this card were checked; absence is not a claim about all public disclosures."},"verified_at":"2026-10-22","coverage":"partial","document_note":"The cited statement is labeled 2025 without an exact publication day; as_of is the access date, not the announcement date.","limitations":["Current relationship is supported by a dated-year company statement; exact publication day and full contract are not disclosed."]}